Zobrazeno 1 - 10
of 11
pro vyhledávání: '"István Laki"'
Autor:
Miroslava Bosheva, Istvan Tokodi, Aleksander Krasnow, Helle Krogh Pedersen, Oksana Lukjancenko, Aron C. Eklund, Dominik Grathwohl, Norbert Sprenger, Bernard Berger, Colin I. Cercamondi, HMO Study Investigator Consortium, Viktor Bauer, Malgorzata Arciszewska, Maria Tarneva, Irina Popova, Svilen Dosev, Sirma Dimitrova, Olga Nikolova, Marzena Nowak, Magdalena Szuflinska-Sidorowicz, Bartosz Korczowski, Rositsa Karcheva-Beloeva, Stefan Banov, Boguslawa Cimoszko, Wieslaw Olechowski, Robert Simko, Zsuzsanna Tengelyi, Piotr Korbal, Marta Zolnowska, Anton Bilev, Georgios Vasilopoulos, Sylwia Korzynska, István Laki, Margarita Koleva-Syarova, Toni Grigorov, Steliyana Kraeva, Éva Kovács, Rada Markova, Grazyna Jasieniak-Pinis, Katalin Fister, Tatyana Stoeva
Publikováno v:
Frontiers in Nutrition, Vol 9 (2022)
BackgroundHuman milk oligosaccharides (HMOs) have important biological functions for a healthy development in early life.ObjectiveThis study aimed to investigate gut maturation effects of an infant formula containing five HMOs (2′-fucosyllactose, 2
Externí odkaz:
https://doaj.org/article/b764f824794a45aaa6aed13c8af2214a
Autor:
István, Laki
Publikováno v:
Gyermekgyógyászat; 2024, Vol. 75 Issue 1, p6-11, 6p
Autor:
Anna Deák, Katalin Koczok, Beáta Bessenyei, Zsuzsanna Szűcs, László Madar, Gabriella Csorba, Orsolya Orosz, István Laki, Adrien Halász, Géza Marsal, István Balogh
Publikováno v:
Orvosi Hetilap. 163:2052-2059
Bevezetés: A cystás fibrosis (CF) az egyik leggyakoribb monogénes betegség. A genetikai vizsgálat a kóros mutációk kiderítésével a diagnózis felállításához, illetve megerősítéséhez egyre inkább elengedhetetlenné válik. A magyar
Autor:
Anna, Deák, Katalin, Koczok, Beáta, Bessenyei, Zsuzsanna, Szűcs, László, Madar, Gabriella, Csorba, Orsolya, Orosz, István, Laki, Adrien, Halász, Géza, Marsal, István, Balogh
Publikováno v:
Orvosi hetilap. 163(51)
Cystic fibrosis (CF) is one of the most common monogenic diseases. Genetic testing is becoming increasingly reasoned to establish or confirm the diagnosis by detecting abnormal mutations.In order to develop a diagnostic strategy for cystic fibrosis a
Autor:
Eckard Hamelmann, Michael Engel, Christian Vogelberg, Ralf Sigmund, Jonathan A. Bernstein, Petra Moroni-Zentgraf, Georges El Azzi, O. Schmidt, István Laki
Publikováno v:
The journal of allergy and clinical immunology. In practice. 6(6)
Autor:
Eckard Hamelmann, Helen Finnigan, Petra Moroni-Zentgraf, Christian Vogelberg, Olaf Schmidt, Michael Engel, István Laki, Georges El Azzi, Mark Vandewalker
Publikováno v:
7.2 Paediatric Asthma and Allergy.
Background: Tiotropium Respimat® (tioR) has been shown to improve lung function in a Phase II study in children with moderate symptomatic asthma. Aim: To assess the efficacy of once-daily tioR add-on therapy in a Phase III trial in patients (pts) ag
Autor:
Michael Engel, Georges El Azzi, Christian Vogelberg, Mark Vandewalker, István Laki, Olaf Schmidt, Eckard Hamelmann, Helen Finnigan, Petra Moroni-Zentgraf
Publikováno v:
7.2 Paediatric Asthma and Allergy.
Background: A Phase II trial has shown tiotropium Respimat ® (tioR) to be a safe and well-tolerated bronchodilator in patients aged 6-11 years with moderate symptomatic asthma. Aim: To further assess safety and tolerability of once-daily tioR add-on
Autor:
Michael Engel, Thomas Harper, István Laki, Stanley J. Szefler, Kevin R. Murphy, Helen Finnigan, Petra Moroni-Zentgraf, Eckard Hamelmann, Attilio Boner, Georges El Azzi
Publikováno v:
The Journal of allergy and clinical immunology. 140(5)
Background Studies in adults and adolescents have demonstrated that tiotropium is efficacious as an add-on therapy to inhaled corticosteroids (ICSs) with or without other maintenance therapies in patients with moderate or severe symptomatic asthma. O
Autor:
G El Azzi, Mark Vandewalker, P. Moroni-Zentgraf, Michael Engel, Eckard Hamelmann, Christian Vogelberg, Helen Finnigan, O. Schmidt, István Laki
Publikováno v:
Thorax. 71:A167.2-A168
Introduction and objectives A Phase II trial has shown that tiotropium Respimat® (tioR) is an effective, safe, and well-tolerated bronchodilator in patients aged 6–11 years with moderate symptomatic asthma.1 To further assess the efficacy and safe
Autor:
István, Laki
Publikováno v:
Gyermekgyógyászat; 2020, Vol. 71 Issue 2, p71-73, 3p